Author:
Ricci Angela Dalia,Rizzo Alessandro,Lotesoriere Claudio
Reference9 articles.
1. Durvalumab or placebo plus gemcitabine and cisplatin in patients with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study;Oh;Lancet Gastroenterol Hepatol,2024
2. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer;Oh;NEJM Evid,2022
3. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial;Kelley;Lancet,2023
4. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial;Burris;Lancet Oncol,2024
5. Health-related quality of life (HRQoL) in the phase 3 KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) versus placebo plus gem/cis for advanced biliary tract cancer (BTC);Yoo;Proc Am Soc Clin Oncol,2023